Elixiron Immunotherapeutics (Cayman) Limited (TPEX:7871)

Taiwan · Delayed Price · Currency is TWD

145.50

+6.50 (4.68%)

At close: Sep 7, 2026

TPEX:7871 Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	113.34	50.29	0.8	25.7
Revenue Growth	125.39%	6162.39%	-96.88%	-
Gross Profit	113.14	49.98	0.17	23.48
Operating Income	-220.07	-196.55	-216.81	-120.95
Net Income	-155.83	-1,107	-440.32	268.21
Earnings Per Share	-1.17	-14.02	-19.90	3.36
EPS Growth	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Investments	808.06	863.36	88.12	30.53
Total Debt	19.56	24.94	1,381	778.35
Net Cash (Debt)	788.5	838.43	-1,293	-747.82
Net Cash Growth	-5.95%	-	-	-
Net Cash Per Share	5.91	10.63	-58.42	-9.36

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Cash Flow	-155.03	-131.97	-239.7	-105.33
Capital Expenditures	-0.5	-0.5	-9.97	-0.22
Free Cash Flow	-155.53	-132.48	-249.67	-105.55
Free Cash Flow Growth	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Gross Margin	99.83%	99.40%	20.67%	91.38%
Operating Margin	-194.17%	-390.85%	-26999.63%	-470.70%
Pretax Margin	-107.54%	-2170.61%	-54833.75%	1058.35%
Profit Margin	-137.48%	-2200.37%	-54833.75%	1043.79%
FCF Margin	-137.23%	-263.44%	-31091.78%	-410.76%